20179196 |
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
Marchio, C,
Ashworth, A,
Reis-Filho, JS,
Lambros, M,
Iorns, E,
Gillett, C,
Geyer, F,
Natrajan, R,
Sharpe, R,
Lopez-Garcia, MA,
Turner, N,
Tutt, A,
Grigoriadis, A,
Mackay, A,
Pearson, A
|
Cancer Res |
2010 |
21160078 |
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
Sietsma, H,
Smit, E,
Solomon, B,
Sollberg, S,
Soltermann, A,
Sos, ML,
Stoelben, E,
Thomas, RK,
Sänger, J,
Timens, W,
Thunnissen, E,
Wagener, P,
Cappuzzo, F,
Buettner, R,
Brustugun, OT,
Brambilla, E,
Brambilla, C,
Baumann, M,
Beroukhim, R,
Baessmann, I,
Balke-Want, H,
Ansén, S,
Altmüller, J,
Zander, T,
Wright, G,
Leenders, F,
Koker, M,
Heynck, S,
Klebl, B,
Heukamp, LC,
Heuckmann, JM,
Hallek, M,
Heideman, D,
Groen, H,
Fischer, F,
Gabler, F,
Ernestus, K,
Engel-Riedel, W,
Damiani, S,
Conron, M,
Dabow, I,
Clement, J,
Seidel, D,
Schöttle, J,
Russell, P,
Rauh, D,
Petersen, I,
Querings, S,
Perner, S,
Nürnberg, P,
Peifer, M,
Moch, H,
Menon, R,
Ludwig, C,
Maier, S,
Ligorio, C,
Lorimier, P,
Wolf, J,
Pao, W,
Weiss, J,
Wainer, Z,
Ullrich, RT
|
Sci Transl Med |
2010 |